Evaluation of Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis Subjects Without an F508del Mutation - Phase 3 - Not yet recruiting
ongoing trials trial from www.clinicaltrials.gov
Details- 2022
- Vertex Pharmaceuticals Incorporated
Efficacy of Intensive Cholecalciferol Monitoring and Supplementation on Serum vitD Levels in Pediatric Patients With CF - Phase 4 - Recruiting
ongoing trials trial from www.clinicaltrials.gov
Details- 2022
- Hospital Infantil de Mexico Federico Gomez
CYstic Fibrosis bacterioPHage Study at Yale (CYPHY) - Phase 1|Phase 2 - Not yet recruiting
ongoing trials trial from www.clinicaltrials.gov
Details- 2021
- Yale University
A New Posaconazole Dosing Regimen for Paediatric Patients With Cystic Fibrosis and Aspergillus Infection - Phase 2|Phase 3 - Recruiting
ongoing trials trial from www.clinicaltrials.gov
Details- 2021
- Bambino Gesù Hospital and Research Institute|University of Exeter|Radboud University|Consorzio per Valutazioni Biologiche e Farmacologiche
Nebulized Bacteriophage Therapy in Cystic Fibrosis Patients With Chronic Pseudomonas Aeruginosa Pulmonary Infection - Phase 1|Phase 2 - Not yet recruiting
ongoing trials trial from www.clinicaltrials.gov
Details- 2021
- BiomX, Inc.
A Phase 3 Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Heterozygous for F508del and a Minimal Function Mutation (F/MF) - Phase 3 - Not yet recruiting
ongoing trials trial from www.clinicaltrials.gov
Details- 2021
- Vertex Pharmaceuticals Incorporated
Study to Evaluate Adverse Events and Change in Disease Activity With Oral Capsules of Galicaftor/Navocaftor/ABBV-119 Combination Therapy in Adult Participants With Cystic Fibrosis - Phase 2 - Not yet recruiting
ongoing trials trial from www.clinicaltrials.gov
Details- 2021
- AbbVie
GLP-1 Agonist Therapy in Cystic Fibrosis-Related Glucose Intolerance - Phase 2 - Not yet recruiting
ongoing trials trial from www.clinicaltrials.gov
Details- 2021
- University of Pennsylvania|Children's Hospital of Philadelphia
Ph 1/2 Study Evaluating Safety and Tolerability of Inhaled AP-PA02 in Subjects With Chronic Pseudomonas Aeruginosa Lung Infections and Cystic Fibrosis - Phase 1|Phase 2 - Recruiting
ongoing trials trial from www.clinicaltrials.gov
Details- 2020
- Armata Pharmaceuticals, Inc.|Cystic Fibrosis Foundation
Effect of Postprandial Insulin Administration of Faster-acting Insulin Analogue Versus Pre-prandial Administration of Acting-insulin Analogue in Cystic Fibrosis Related Diabetes - Phase 4 - Not yet recruiting
ongoing trials trial from www.clinicaltrials.gov
Details- 2020
- University Hospital, Strasbourg, France